Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity
COVID-19; Severe acute respiratory syndrome; Data set COVID-19; Síndrome respiratorio agudo severo; Conjunto de datos COVID-19; Síndrome respiratòria aguda severa; Conjunt de dades Background and Objectives Certain demographic and clinical characteristics, including the use of some disease-modifying...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Simpson-Yap, Steve Pirmani, Ashkan Kalincik, Tomas De Brouwer, Edward Geys, Lotte Parciak, Tina Zabalza de Torres, Ana Arrambide García, Georgina |
| description | COVID-19; Severe acute respiratory syndrome; Data set
COVID-19; Síndrome respiratorio agudo severo; Conjunto de datos
COVID-19; Síndrome respiratòria aguda severa; Conjunt de dades
Background and Objectives Certain demographic and clinical characteristics, including the use of some disease-modifying therapies (DMTs), are associated with severe acute respiratory syndrome coronavirus 2 infection severity in people with multiple sclerosis (MS). Comprehensive exploration of these relationships in large international samples is needed.
Methods Clinician-reported demographic/clinical data from 27 countries were aggregated into a data set of 5,648 patients with suspected/confirmed coronavirus disease 2019 (COVID-19). COVID-19 severity outcomes (hospitalization, admission to intensive care unit [ICU], requiring artificial ventilation, and death) were assessed using multilevel mixed-effects ordered probit and logistic regression, adjusted for age, sex, disability, and MS phenotype. DMTs were individually compared with glatiramer acetate, and anti-CD20 DMTs with pooled other DMTs and with natalizumab.
Results Of 5,648 patients, 922 (16.6%) with suspected and 4,646 (83.4%) with confirmed COVID-19 were included. Male sex, older age, progressive MS, and higher disability were associated with more severe COVID-19. Compared with glatiramer acetate, ocrelizumab and rituximab were associated with higher probabilities of hospitalization (4% [95% CI 1–7] and 7% [95% CI 4–11]), ICU/artificial ventilation (2% [95% CI 0–4] and 4% [95% CI 2–6]), and death (1% [95% CI 0–2] and 2% [95% CI 1–4]) (predicted marginal effects). Untreated patients had 5% (95% CI 2–8), 3% (95% CI 1–5), and 1% (95% CI 0–3) higher probabilities of the 3 respective levels of COVID-19 severity than glatiramer acetate. Compared with pooled other DMTs and with natalizumab, the associations of ocrelizumab and rituximab with COVID-19 severity were also more pronounced. All associations persisted/enhanced on restriction to confirmed COVID-19.
Discussion Analyzing the largest international real-world data set of people with MS with suspected/confirmed COVID-19 confirms that the use of anti-CD20 medication (both ocrelizumab and rituximab), as well as male sex, older age, progressive MS, and higher disability are associated with more severe course of COVID-19.
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the operational costs li |
| format | Article |
| fullrecord | <record><control><sourceid>csuc_XX2</sourceid><recordid>TN_cdi_csuc_recercat_oai_recercat_cat_11351_8427</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_recercat_cat_11351_8427</sourcerecordid><originalsourceid>FETCH-csuc_recercat_oai_recercat_cat_11351_84273</originalsourceid><addsrcrecordid>eNqdjUkKwkAQRbNxIeod6gKBxAGHnSQOWUggcViGslOawtAt3WXAG3hsBwT3Lj6fv3jvt73H7lqiUAkZuVstDswJpCKI0n0S--EUWMMmh1VtjlhDjIKQV2hZnyHRLIzCDc1groX9KO4HgLqE9GWwkLG7wBKVGOtg7pxR_Hk6sFQ_f04NWZZ712udsHbU-3bHC5aLbbT2lbupwpIiq1AKg_wb74ThYBQWk2F_PPgDeQJ_xVQp</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity</title><source>Recercat</source><creator>Simpson-Yap, Steve ; Pirmani, Ashkan ; Kalincik, Tomas ; De Brouwer, Edward ; Geys, Lotte ; Parciak, Tina ; Zabalza de Torres, Ana ; Arrambide García, Georgina</creator><creatorcontrib>Simpson-Yap, Steve ; Pirmani, Ashkan ; Kalincik, Tomas ; De Brouwer, Edward ; Geys, Lotte ; Parciak, Tina ; Zabalza de Torres, Ana ; Arrambide García, Georgina</creatorcontrib><description>COVID-19; Severe acute respiratory syndrome; Data set
COVID-19; Síndrome respiratorio agudo severo; Conjunto de datos
COVID-19; Síndrome respiratòria aguda severa; Conjunt de dades
Background and Objectives Certain demographic and clinical characteristics, including the use of some disease-modifying therapies (DMTs), are associated with severe acute respiratory syndrome coronavirus 2 infection severity in people with multiple sclerosis (MS). Comprehensive exploration of these relationships in large international samples is needed.
Methods Clinician-reported demographic/clinical data from 27 countries were aggregated into a data set of 5,648 patients with suspected/confirmed coronavirus disease 2019 (COVID-19). COVID-19 severity outcomes (hospitalization, admission to intensive care unit [ICU], requiring artificial ventilation, and death) were assessed using multilevel mixed-effects ordered probit and logistic regression, adjusted for age, sex, disability, and MS phenotype. DMTs were individually compared with glatiramer acetate, and anti-CD20 DMTs with pooled other DMTs and with natalizumab.
Results Of 5,648 patients, 922 (16.6%) with suspected and 4,646 (83.4%) with confirmed COVID-19 were included. Male sex, older age, progressive MS, and higher disability were associated with more severe COVID-19. Compared with glatiramer acetate, ocrelizumab and rituximab were associated with higher probabilities of hospitalization (4% [95% CI 1–7] and 7% [95% CI 4–11]), ICU/artificial ventilation (2% [95% CI 0–4] and 4% [95% CI 2–6]), and death (1% [95% CI 0–2] and 2% [95% CI 1–4]) (predicted marginal effects). Untreated patients had 5% (95% CI 2–8), 3% (95% CI 1–5), and 1% (95% CI 0–3) higher probabilities of the 3 respective levels of COVID-19 severity than glatiramer acetate. Compared with pooled other DMTs and with natalizumab, the associations of ocrelizumab and rituximab with COVID-19 severity were also more pronounced. All associations persisted/enhanced on restriction to confirmed COVID-19.
Discussion Analyzing the largest international real-world data set of people with MS with suspected/confirmed COVID-19 confirms that the use of anti-CD20 medication (both ocrelizumab and rituximab), as well as male sex, older age, progressive MS, and higher disability are associated with more severe course of COVID-19.
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the operational costs linked to this study are funded by the Multiple Sclerosis International Federation (MSIF) and the Multiple Sclerosis Data Alliance (MSDA), acting under the umbrella of the European Charcot Foundation (ECF). The MSDA receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Canopy Growth Corporation, Genzyme, Icometrix, Merck, Mylan, Novartis, QMENTA, Quanterix, and Roche. MSIF receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Genzyme, Med-Day, Merck, Mylan, Novartis, and Roche. This work was supported by the Flemish Government under the Onderzoeksprogramma Artificiële Intelligentie (AI) Vlaanderen programme and the Research Foundation Fladers (FWO) for ELIXIR Belgium—Flanders (FWO) for ELIXIR Belgium. The central platform was provided by QMENTA, and the computational resources used in this work were provided by Amazon. The statistical analysis was carried out at CORe, The University of Melbourne, with support from NHMRC (1129189 and 1140766).</description><language>eng</language><publisher>Lippincott, Williams & Wilkins</publisher><subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT ; Autoimmune Diseases of the Nervous System ; Coronaviridae Infections ; Coronavirus Infections ; COVID-19 (Malaltia) - Factors de risc ; Demyelinating Autoimmune Diseases, CNS ; DISEASES ; ENFERMEDADES ; enfermedades autoinmunes desmielinizantes del SNC ; enfermedades autoinmunitarias del sistema nervioso ; enfermedades del sistema nervioso ; Epidemiologic Methods ; Esclerosi múltiple ; esclerosis múltiple ; estadística como asunto ; factores de riesgo ; infecciones por Coronaviridae ; infecciones por Coronavirus ; infecciones por Nidovirales ; infecciones por virus ARN ; Investigative Techniques ; Multiple Sclerosis ; métodos epidemiológicos ; Nervous System Diseases ; Nidovirales Infections ; probabilidad ; Probability ; riesgo ; Risk ; Risk Factors ; RNA Virus Infections ; Statistics as Topic ; técnicas de investigación ; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS ; virosis ; Virus Diseases</subject><creationdate>2022-11</creationdate><rights>Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,782,887,26981</link.rule.ids><linktorsrc>$$Uhttps://recercat.cat/handle/11351/8427$$EView_record_in_Consorci_de_Serveis_Universitaris_de_Catalunya_(CSUC)$$FView_record_in_$$GConsorci_de_Serveis_Universitaris_de_Catalunya_(CSUC)$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Simpson-Yap, Steve</creatorcontrib><creatorcontrib>Pirmani, Ashkan</creatorcontrib><creatorcontrib>Kalincik, Tomas</creatorcontrib><creatorcontrib>De Brouwer, Edward</creatorcontrib><creatorcontrib>Geys, Lotte</creatorcontrib><creatorcontrib>Parciak, Tina</creatorcontrib><creatorcontrib>Zabalza de Torres, Ana</creatorcontrib><creatorcontrib>Arrambide García, Georgina</creatorcontrib><title>Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity</title><description>COVID-19; Severe acute respiratory syndrome; Data set
COVID-19; Síndrome respiratorio agudo severo; Conjunto de datos
COVID-19; Síndrome respiratòria aguda severa; Conjunt de dades
Background and Objectives Certain demographic and clinical characteristics, including the use of some disease-modifying therapies (DMTs), are associated with severe acute respiratory syndrome coronavirus 2 infection severity in people with multiple sclerosis (MS). Comprehensive exploration of these relationships in large international samples is needed.
Methods Clinician-reported demographic/clinical data from 27 countries were aggregated into a data set of 5,648 patients with suspected/confirmed coronavirus disease 2019 (COVID-19). COVID-19 severity outcomes (hospitalization, admission to intensive care unit [ICU], requiring artificial ventilation, and death) were assessed using multilevel mixed-effects ordered probit and logistic regression, adjusted for age, sex, disability, and MS phenotype. DMTs were individually compared with glatiramer acetate, and anti-CD20 DMTs with pooled other DMTs and with natalizumab.
Results Of 5,648 patients, 922 (16.6%) with suspected and 4,646 (83.4%) with confirmed COVID-19 were included. Male sex, older age, progressive MS, and higher disability were associated with more severe COVID-19. Compared with glatiramer acetate, ocrelizumab and rituximab were associated with higher probabilities of hospitalization (4% [95% CI 1–7] and 7% [95% CI 4–11]), ICU/artificial ventilation (2% [95% CI 0–4] and 4% [95% CI 2–6]), and death (1% [95% CI 0–2] and 2% [95% CI 1–4]) (predicted marginal effects). Untreated patients had 5% (95% CI 2–8), 3% (95% CI 1–5), and 1% (95% CI 0–3) higher probabilities of the 3 respective levels of COVID-19 severity than glatiramer acetate. Compared with pooled other DMTs and with natalizumab, the associations of ocrelizumab and rituximab with COVID-19 severity were also more pronounced. All associations persisted/enhanced on restriction to confirmed COVID-19.
Discussion Analyzing the largest international real-world data set of people with MS with suspected/confirmed COVID-19 confirms that the use of anti-CD20 medication (both ocrelizumab and rituximab), as well as male sex, older age, progressive MS, and higher disability are associated with more severe course of COVID-19.
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the operational costs linked to this study are funded by the Multiple Sclerosis International Federation (MSIF) and the Multiple Sclerosis Data Alliance (MSDA), acting under the umbrella of the European Charcot Foundation (ECF). The MSDA receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Canopy Growth Corporation, Genzyme, Icometrix, Merck, Mylan, Novartis, QMENTA, Quanterix, and Roche. MSIF receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Genzyme, Med-Day, Merck, Mylan, Novartis, and Roche. This work was supported by the Flemish Government under the Onderzoeksprogramma Artificiële Intelligentie (AI) Vlaanderen programme and the Research Foundation Fladers (FWO) for ELIXIR Belgium—Flanders (FWO) for ELIXIR Belgium. The central platform was provided by QMENTA, and the computational resources used in this work were provided by Amazon. The statistical analysis was carried out at CORe, The University of Melbourne, with support from NHMRC (1129189 and 1140766).</description><subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT</subject><subject>Autoimmune Diseases of the Nervous System</subject><subject>Coronaviridae Infections</subject><subject>Coronavirus Infections</subject><subject>COVID-19 (Malaltia) - Factors de risc</subject><subject>Demyelinating Autoimmune Diseases, CNS</subject><subject>DISEASES</subject><subject>ENFERMEDADES</subject><subject>enfermedades autoinmunes desmielinizantes del SNC</subject><subject>enfermedades autoinmunitarias del sistema nervioso</subject><subject>enfermedades del sistema nervioso</subject><subject>Epidemiologic Methods</subject><subject>Esclerosi múltiple</subject><subject>esclerosis múltiple</subject><subject>estadística como asunto</subject><subject>factores de riesgo</subject><subject>infecciones por Coronaviridae</subject><subject>infecciones por Coronavirus</subject><subject>infecciones por Nidovirales</subject><subject>infecciones por virus ARN</subject><subject>Investigative Techniques</subject><subject>Multiple Sclerosis</subject><subject>métodos epidemiológicos</subject><subject>Nervous System Diseases</subject><subject>Nidovirales Infections</subject><subject>probabilidad</subject><subject>Probability</subject><subject>riesgo</subject><subject>Risk</subject><subject>Risk Factors</subject><subject>RNA Virus Infections</subject><subject>Statistics as Topic</subject><subject>técnicas de investigación</subject><subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS</subject><subject>virosis</subject><subject>Virus Diseases</subject><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>XX2</sourceid><recordid>eNqdjUkKwkAQRbNxIeod6gKBxAGHnSQOWUggcViGslOawtAt3WXAG3hsBwT3Lj6fv3jvt73H7lqiUAkZuVstDswJpCKI0n0S--EUWMMmh1VtjlhDjIKQV2hZnyHRLIzCDc1groX9KO4HgLqE9GWwkLG7wBKVGOtg7pxR_Hk6sFQ_f04NWZZ712udsHbU-3bHC5aLbbT2lbupwpIiq1AKg_wb74ThYBQWk2F_PPgDeQJ_xVQp</recordid><startdate>202211</startdate><enddate>202211</enddate><creator>Simpson-Yap, Steve</creator><creator>Pirmani, Ashkan</creator><creator>Kalincik, Tomas</creator><creator>De Brouwer, Edward</creator><creator>Geys, Lotte</creator><creator>Parciak, Tina</creator><creator>Zabalza de Torres, Ana</creator><creator>Arrambide García, Georgina</creator><general>Lippincott, Williams & Wilkins</general><scope>XX2</scope></search><sort><creationdate>202211</creationdate><title>Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity</title><author>Simpson-Yap, Steve ; Pirmani, Ashkan ; Kalincik, Tomas ; De Brouwer, Edward ; Geys, Lotte ; Parciak, Tina ; Zabalza de Torres, Ana ; Arrambide García, Georgina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-csuc_recercat_oai_recercat_cat_11351_84273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT</topic><topic>Autoimmune Diseases of the Nervous System</topic><topic>Coronaviridae Infections</topic><topic>Coronavirus Infections</topic><topic>COVID-19 (Malaltia) - Factors de risc</topic><topic>Demyelinating Autoimmune Diseases, CNS</topic><topic>DISEASES</topic><topic>ENFERMEDADES</topic><topic>enfermedades autoinmunes desmielinizantes del SNC</topic><topic>enfermedades autoinmunitarias del sistema nervioso</topic><topic>enfermedades del sistema nervioso</topic><topic>Epidemiologic Methods</topic><topic>Esclerosi múltiple</topic><topic>esclerosis múltiple</topic><topic>estadística como asunto</topic><topic>factores de riesgo</topic><topic>infecciones por Coronaviridae</topic><topic>infecciones por Coronavirus</topic><topic>infecciones por Nidovirales</topic><topic>infecciones por virus ARN</topic><topic>Investigative Techniques</topic><topic>Multiple Sclerosis</topic><topic>métodos epidemiológicos</topic><topic>Nervous System Diseases</topic><topic>Nidovirales Infections</topic><topic>probabilidad</topic><topic>Probability</topic><topic>riesgo</topic><topic>Risk</topic><topic>Risk Factors</topic><topic>RNA Virus Infections</topic><topic>Statistics as Topic</topic><topic>técnicas de investigación</topic><topic>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS</topic><topic>virosis</topic><topic>Virus Diseases</topic><toplevel>online_resources</toplevel><creatorcontrib>Simpson-Yap, Steve</creatorcontrib><creatorcontrib>Pirmani, Ashkan</creatorcontrib><creatorcontrib>Kalincik, Tomas</creatorcontrib><creatorcontrib>De Brouwer, Edward</creatorcontrib><creatorcontrib>Geys, Lotte</creatorcontrib><creatorcontrib>Parciak, Tina</creatorcontrib><creatorcontrib>Zabalza de Torres, Ana</creatorcontrib><creatorcontrib>Arrambide García, Georgina</creatorcontrib><collection>Recercat</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Simpson-Yap, Steve</au><au>Pirmani, Ashkan</au><au>Kalincik, Tomas</au><au>De Brouwer, Edward</au><au>Geys, Lotte</au><au>Parciak, Tina</au><au>Zabalza de Torres, Ana</au><au>Arrambide García, Georgina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity</atitle><date>2022-11</date><risdate>2022</risdate><abstract>COVID-19; Severe acute respiratory syndrome; Data set
COVID-19; Síndrome respiratorio agudo severo; Conjunto de datos
COVID-19; Síndrome respiratòria aguda severa; Conjunt de dades
Background and Objectives Certain demographic and clinical characteristics, including the use of some disease-modifying therapies (DMTs), are associated with severe acute respiratory syndrome coronavirus 2 infection severity in people with multiple sclerosis (MS). Comprehensive exploration of these relationships in large international samples is needed.
Methods Clinician-reported demographic/clinical data from 27 countries were aggregated into a data set of 5,648 patients with suspected/confirmed coronavirus disease 2019 (COVID-19). COVID-19 severity outcomes (hospitalization, admission to intensive care unit [ICU], requiring artificial ventilation, and death) were assessed using multilevel mixed-effects ordered probit and logistic regression, adjusted for age, sex, disability, and MS phenotype. DMTs were individually compared with glatiramer acetate, and anti-CD20 DMTs with pooled other DMTs and with natalizumab.
Results Of 5,648 patients, 922 (16.6%) with suspected and 4,646 (83.4%) with confirmed COVID-19 were included. Male sex, older age, progressive MS, and higher disability were associated with more severe COVID-19. Compared with glatiramer acetate, ocrelizumab and rituximab were associated with higher probabilities of hospitalization (4% [95% CI 1–7] and 7% [95% CI 4–11]), ICU/artificial ventilation (2% [95% CI 0–4] and 4% [95% CI 2–6]), and death (1% [95% CI 0–2] and 2% [95% CI 1–4]) (predicted marginal effects). Untreated patients had 5% (95% CI 2–8), 3% (95% CI 1–5), and 1% (95% CI 0–3) higher probabilities of the 3 respective levels of COVID-19 severity than glatiramer acetate. Compared with pooled other DMTs and with natalizumab, the associations of ocrelizumab and rituximab with COVID-19 severity were also more pronounced. All associations persisted/enhanced on restriction to confirmed COVID-19.
Discussion Analyzing the largest international real-world data set of people with MS with suspected/confirmed COVID-19 confirms that the use of anti-CD20 medication (both ocrelizumab and rituximab), as well as male sex, older age, progressive MS, and higher disability are associated with more severe course of COVID-19.
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the operational costs linked to this study are funded by the Multiple Sclerosis International Federation (MSIF) and the Multiple Sclerosis Data Alliance (MSDA), acting under the umbrella of the European Charcot Foundation (ECF). The MSDA receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Canopy Growth Corporation, Genzyme, Icometrix, Merck, Mylan, Novartis, QMENTA, Quanterix, and Roche. MSIF receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Genzyme, Med-Day, Merck, Mylan, Novartis, and Roche. This work was supported by the Flemish Government under the Onderzoeksprogramma Artificiële Intelligentie (AI) Vlaanderen programme and the Research Foundation Fladers (FWO) for ELIXIR Belgium—Flanders (FWO) for ELIXIR Belgium. The central platform was provided by QMENTA, and the computational resources used in this work were provided by Amazon. The statistical analysis was carried out at CORe, The University of Melbourne, with support from NHMRC (1129189 and 1140766).</abstract><pub>Lippincott, Williams & Wilkins</pub><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_csuc_recercat_oai_recercat_cat_11351_8427 |
| source | Recercat |
| subjects | ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT Autoimmune Diseases of the Nervous System Coronaviridae Infections Coronavirus Infections COVID-19 (Malaltia) - Factors de risc Demyelinating Autoimmune Diseases, CNS DISEASES ENFERMEDADES enfermedades autoinmunes desmielinizantes del SNC enfermedades autoinmunitarias del sistema nervioso enfermedades del sistema nervioso Epidemiologic Methods Esclerosi múltiple esclerosis múltiple estadística como asunto factores de riesgo infecciones por Coronaviridae infecciones por Coronavirus infecciones por Nidovirales infecciones por virus ARN Investigative Techniques Multiple Sclerosis métodos epidemiológicos Nervous System Diseases Nidovirales Infections probabilidad Probability riesgo Risk Risk Factors RNA Virus Infections Statistics as Topic técnicas de investigación TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS virosis Virus Diseases |
| title | Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T03%3A50%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-csuc_XX2&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Updated%20Results%20of%20the%20COVID-19%20in%20MS%20Global%20Data%20Sharing%20Initiative:%20Anti-CD20%20and%20Other%20Risk%20Factors%20Associated%20With%20COVID-19%20Severity&rft.au=Simpson-Yap,%20Steve&rft.date=2022-11&rft_id=info:doi/&rft_dat=%3Ccsuc_XX2%3Eoai_recercat_cat_11351_8427%3C/csuc_XX2%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |